MX2023007869A - Compuestos que comprenden un ligando de proteina de activacion de fibroblasto y uso del mismo. - Google Patents
Compuestos que comprenden un ligando de proteina de activacion de fibroblasto y uso del mismo.Info
- Publication number
- MX2023007869A MX2023007869A MX2023007869A MX2023007869A MX2023007869A MX 2023007869 A MX2023007869 A MX 2023007869A MX 2023007869 A MX2023007869 A MX 2023007869A MX 2023007869 A MX2023007869 A MX 2023007869A MX 2023007869 A MX2023007869 A MX 2023007869A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- activation protein
- protein ligand
- fibroblast activation
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000004913 activation Effects 0.000 title 1
- 210000002950 fibroblast Anatomy 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 108010069514 Cyclic Peptides Proteins 0.000 abstract 1
- 102000001189 Cyclic Peptides Human genes 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 238000011191 terminal modification Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8103—Exopeptidase (E.C. 3.4.11-19) inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14001—Dipeptidyl-peptidase I (3.4.14.1), i.e. cathepsin-C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21026—Prolyl oligopeptidase (3.4.21.26), i.e. proline-specific endopeptidase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Optics & Photonics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163134704P | 2021-01-07 | 2021-01-07 | |
| PCT/EP2022/050280 WO2022148843A1 (en) | 2021-01-07 | 2022-01-07 | Compounds comprising a fibroblast activation protein ligand and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007869A true MX2023007869A (es) | 2023-09-22 |
Family
ID=80050672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007869A MX2023007869A (es) | 2021-01-07 | 2022-01-07 | Compuestos que comprenden un ligando de proteina de activacion de fibroblasto y uso del mismo. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230212549A1 (https=) |
| EP (1) | EP4274835A1 (https=) |
| JP (1) | JP2024503637A (https=) |
| KR (1) | KR20230129261A (https=) |
| CN (1) | CN116940585A (https=) |
| AU (1) | AU2022205523A1 (https=) |
| CA (1) | CA3206863A1 (https=) |
| CL (5) | CL2023001991A1 (https=) |
| IL (1) | IL303925A (https=) |
| MX (1) | MX2023007869A (https=) |
| WO (1) | WO2022148843A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220072092A1 (en) * | 2016-06-24 | 2022-03-10 | University Of Iowa Research Foundation | Compositions and methods of treating melanoma |
| FI3997103T3 (fi) | 2019-07-08 | 2025-02-03 | 3B Pharmaceuticals Gmbh | Fibroblastien aktivaatioproteiinin ligandia käsittäviä yhdisteitä ja niiden käyttö |
| EP4475900A1 (en) | 2022-02-09 | 2024-12-18 | Novartis AG | Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent |
| EP4692105A1 (en) * | 2023-03-27 | 2026-02-11 | Bivision Pharmaceuticals, Inc | Cyclic polypeptide compound and use thereof |
| WO2024198836A1 (zh) * | 2023-03-27 | 2024-10-03 | 晶核生物医药科技(南京)有限公司 | 环状多肽类化合物及其应用 |
| WO2024198838A1 (zh) * | 2023-03-27 | 2024-10-03 | 晶核生物医药科技(南京)有限公司 | 环状多肽类化合物及其应用 |
| CN118930606A (zh) * | 2023-05-11 | 2024-11-12 | 成都纽瑞特医疗科技股份有限公司 | 靶向成纤维细胞活化蛋白的多肽放射性核素配合物及其应用 |
| KR20260026051A (ko) * | 2023-06-14 | 2026-02-25 | 마리아나 온콜로지 인크. | Dll3 표적화 펩티드 및 이의 구성체 |
| CN121712787A (zh) * | 2023-06-14 | 2026-03-20 | 马里亚纳肿瘤学公司 | 靶向dll3的肽及其构建体 |
| CN121712788A (zh) * | 2023-06-14 | 2026-03-20 | 马里亚纳肿瘤学公司 | 靶向dll3的肽及其构建体 |
| WO2025011611A1 (zh) * | 2023-07-11 | 2025-01-16 | 江苏恒瑞医药股份有限公司 | 一种成纤维细胞活化蛋白配体及其用途 |
| WO2025082283A1 (zh) * | 2023-10-16 | 2025-04-24 | 四川科伦博泰生物医药股份有限公司 | 环肽结构的配体化合物及其核素标记物、药物组合物及应用 |
| WO2025117586A1 (en) * | 2023-11-27 | 2025-06-05 | Mariana Oncology Inc. | Dll3 targeting peptides and constructs thereof |
| US20250186630A1 (en) * | 2023-12-12 | 2025-06-12 | Viewpoint Molecular Targeting, Inc. | Fibroblast activation protein targeting peptides |
| WO2025163556A1 (en) | 2024-02-01 | 2025-08-07 | Novartis Ag | Methods for treating cancer |
| TW202600606A (zh) * | 2024-02-21 | 2026-01-01 | 美商雅博得樂醫療公司 | 抗體連接子結合物 |
| WO2025179168A1 (en) * | 2024-02-22 | 2025-08-28 | Mariana Oncology Inc. | Synthesis of dll3-binding peptides |
| WO2025252221A1 (zh) * | 2024-06-07 | 2025-12-11 | 中国科学院上海药物研究所 | 一类靶向肿瘤相关成纤维细胞激活蛋白的糖肽、放射性核素标记物及其应用 |
| CN121045338A (zh) * | 2025-11-05 | 2025-12-02 | 原子高科股份有限公司 | 一种靶向caix的环肽及其制备方法与应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4885363A (en) | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| US5021556A (en) | 1987-07-22 | 1991-06-04 | Neorx Corporation | Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides |
| US5075099A (en) | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| US5367080A (en) | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
| US5886142A (en) | 1997-05-20 | 1999-03-23 | Thomas Jefferson University | Radiolabeled thrombus imaging agents |
| ATE357509T1 (de) | 1997-09-29 | 2007-04-15 | Point Therapeutics Inc | Stimulierung von hämatopoietischen zellen im vitro |
| EP0953639A1 (en) | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
| US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
| EP1268550A2 (en) | 2000-03-17 | 2003-01-02 | Boehringer Ingelheim Pharma KG | Human fap-alpha-specific antibodies |
| US7374898B2 (en) | 2004-10-12 | 2008-05-20 | The Research Foundation Of State University Of New York | Peptide inhibitors against seprase |
| US7399869B2 (en) | 2005-05-19 | 2008-07-15 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
| US8933201B2 (en) | 2006-06-07 | 2015-01-13 | The Board Of Regents Of The University Of Oklahoma | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use |
| WO2008116054A1 (en) | 2007-03-20 | 2008-09-25 | Trustees Of Tufts College | Inhibitors of fibroblast activation protein, and methods of use thereof |
| WO2010036814A1 (en) | 2008-09-25 | 2010-04-01 | Molecular Insight Pharmaceuticals, Inc. | Selective seprase inhibitors |
| CA2776037A1 (en) | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd | Anti-fibroblast activation protein antibodies and methods and uses thereof |
| CA2806021C (en) | 2010-08-13 | 2019-05-21 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
| WO2013107820A1 (en) | 2012-01-17 | 2013-07-25 | Universiteit Antwerpen | Novel fap inhibitors |
| UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| GB201402006D0 (en) | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
| WO2016146174A1 (en) * | 2015-03-17 | 2016-09-22 | Biontech Ag | Compositions and methods for diagnosis and treatment of cancer |
| CN109689115A (zh) | 2016-06-10 | 2019-04-26 | 拜耳制药股份公司 | 放射性药物配合物 |
| JP2018035137A (ja) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ | 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用 |
| EA202090776A1 (ru) * | 2017-10-23 | 2020-07-27 | Дзе Джонс Хопкинс Юниверсити | Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha) |
| EP3763726A1 (en) * | 2019-07-08 | 2021-01-13 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
-
2022
- 2022-01-07 IL IL303925A patent/IL303925A/en unknown
- 2022-01-07 MX MX2023007869A patent/MX2023007869A/es unknown
- 2022-01-07 CA CA3206863A patent/CA3206863A1/en active Pending
- 2022-01-07 EP EP22700892.7A patent/EP4274835A1/en active Pending
- 2022-01-07 WO PCT/EP2022/050280 patent/WO2022148843A1/en not_active Ceased
- 2022-01-07 CN CN202280019456.5A patent/CN116940585A/zh active Pending
- 2022-01-07 KR KR1020237026404A patent/KR20230129261A/ko active Pending
- 2022-01-07 US US17/571,067 patent/US20230212549A1/en active Pending
- 2022-01-07 AU AU2022205523A patent/AU2022205523A1/en active Pending
- 2022-01-07 JP JP2023541264A patent/JP2024503637A/ja active Pending
-
2023
- 2023-07-06 CL CL2023001991A patent/CL2023001991A1/es unknown
-
2024
- 2024-05-28 CL CL2024001600A patent/CL2024001600A1/es unknown
- 2024-05-28 CL CL2024001597A patent/CL2024001597A1/es unknown
- 2024-05-28 CL CL2024001599A patent/CL2024001599A1/es unknown
- 2024-05-28 CL CL2024001596A patent/CL2024001596A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2024001597A1 (es) | 2024-10-11 |
| EP4274835A1 (en) | 2023-11-15 |
| JP2024503637A (ja) | 2024-01-26 |
| IL303925A (en) | 2023-08-01 |
| CL2024001600A1 (es) | 2024-10-11 |
| CN116940585A (zh) | 2023-10-24 |
| CA3206863A1 (en) | 2022-07-14 |
| CL2023001991A1 (es) | 2023-12-15 |
| WO2022148843A1 (en) | 2022-07-14 |
| CL2024001596A1 (es) | 2024-10-11 |
| US20230212549A1 (en) | 2023-07-06 |
| CL2024001599A1 (es) | 2024-10-11 |
| AU2022205523A1 (en) | 2023-07-13 |
| KR20230129261A (ko) | 2023-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023007869A (es) | Compuestos que comprenden un ligando de proteina de activacion de fibroblasto y uso del mismo. | |
| CL2022000016A1 (es) | Compuestos que comprenden un ligando de proteína de activación de fibroblasto y uso del mismo | |
| RU2012147267A (ru) | Эффективные аналоги компстатина | |
| PE20091753A1 (es) | Conjugados antagonistas peptidicos analogos a la bombesina | |
| ATE540054T1 (de) | Antimikrobielle theta defensine und verfahren zu deren verwendung | |
| FI3299383T3 (fi) | Vasta-aineen erityinen modifikaatio igg-sitoutuvalla peptidillä | |
| PE20061448A1 (es) | Compuestos polipeptidos como moduladores del peptido 1 similar al glucagon humano | |
| CO6150201A2 (es) | Anticuerpo humanizado contra beta amiloide | |
| RU2016147080A (ru) | Модуляция активности комплемента | |
| CA2651990C (en) | Improved antimicrobial peptides | |
| Suwal et al. | Synthesis of libraries of peptidomimetic compounds containing a 2-oxopiperazine unit in the main chain | |
| AR128023A1 (es) | Ligandos de anhidrasa carbónica ix | |
| WO2023072971A3 (en) | Gastric inhibitory peptide receptor ligands | |
| DK1587830T3 (da) | Peptidinhibitorer af toksiner stammende fra LL-37 | |
| JP6388872B2 (ja) | ポリペプチド組成物およびこれを用いた多能性幹細胞の培養方法 | |
| CO2024010813A2 (es) | Inhibidor de tsp1 | |
| ES2607490T3 (es) | Péptidos antienvejecimiento activadores del proteasoma y composiciones que los contienen | |
| BR112015018283A2 (pt) | Composto peptídico agonista e composição farmacêutica ou veterinária | |
| DK1691827T3 (da) | Anvendelse af peptider, der er afledt fra beta-kæden af det humane fibrinogen, til behandlling af shock | |
| US20180208902A1 (en) | Method for culturing pluripotent stem cells, method for manufacturing culture vessel, culture vessel, and scaffold material for culturing cells | |
| Sato et al. | Novel des-fatty acyl-polymyxin B derivatives with Pseudomonas aeruginosa-specific antimicrobial activity | |
| RU2013145467A (ru) | Композиции для предупреждения и/или лечения инфекции, вызванной вирусом вич-1 | |
| MY151307A (en) | Peptides having antimicrobial activity | |
| CR20240470A (es) | Péptido con actividad antimicrobiana | |
| WO2006108686A3 (en) | Bnp agonists |